GOODTCELLS succeeds in attracting KRW 5 billion from Yuhan Corporation

Published: 2018-07-26 13:01:53

Updated: 2018-07-26 13:06:56

GOODTCELLS, a biopharmaceutical venture specializing in immune disorder therapies, announced on the 23^rd that the company succeeded in attracting a KRW 5 billion investment from Yuhan Corporation(CEO Jung-Hee Lee).

Yuhan Corporation will keep 6.25% of the company share by investing KRW 5 billion into convertible stocks and will jointly develop new immune disorder therapies.

GOODTCELLS was fou...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.